Three Experimental Drugs Advance in ME/CFS, POTS Research
Recent drug-development coverage highlights a push to match treatments to patient biology, alongside the challenge of moving promising research into clinical use. An account of three investigational therapies for ME/CFS, long COVID and POTS emphasizes that biological subgroups may respond differently, while noting that some evidence is preliminary or not statistically significant across the full study population. Drug-discovery symposia at the University of Miami and Oregon Health & Science University are focused on connecting scientific findings with development, industry collaboration and potential treatments. Meanwhile, a review of possible 2027 drug launches points to commercial access, emerging treatment platforms and regulators’ acceptance of surrogate measures as important factors in whether therapies reach patients.
Claim check
What each side asserts, disputes — or leaves out entirely.
Where do you land?
Whose framing of this story rings truest to you?




